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PPRECLINICAL RESEARCH
Clarithromycin Attenuates Acute and
Chronic Rejection Via Matrix Metalloproteinase
Suppression in Murine Cardiac Transplantation
Masahito Ogawa, BS,* Jun-ichi Suzuki, MD,* Keiichi Hishikari, BS,* Kiyoshi Takayama, PHD,*
Hiroyuki Tanaka, MD, PHD,† Mitsuaki Isobe, MD, PHD*
Tokyo, Japan
Objectives Clarithromycin (CAM), a major macrolide antibiotic, has many biological functions, including matrix metallopro-
teinases (MMPs) regulation. However, little is known about the effect of CAM in heart transplantation via MMP-9.
The purpose of this study was to clarify the role of MMPs regulated by CAM in the progression of rejection.
Background The MMPs are critical in the development of inflammation and tissue remodeling. The MMP-9 level is associated
with the rejection of heart transplantation.
Methods We orally administered CAM into murine cardiac allograft recipients. Total allomismatch combination and class
II mismatch combination were used for the analysis of graft survival, pathology and molecular.
Results Clarithromycin improved acute rejection judged by graft survival and by myocardial cell infiltrating area in a total
allomismatch combination. The CAM-treated allografts showed affected expression of T-cells, macrophages, and
MMP-9 in immunohistochemistry. Zymography indicated that enhanced MMPs activities were observed in non-
treated hearts, whereas CAM suppressed the levels. In chronic rejection, CAM suppressed the development of
graft arterial disease and myocardial remodeling compared with that of nontreatment. Clarithromycin inhibited
the expression of MMP-9, whereas the treatment did not alter the expression of MMP-2 and tissue inhibitor
metalloproteinase-1 in macrophages and smooth muscle cells. Inhibition of MMP-9 by CAM was associated with
suppression of smooth muscle cell migration and proliferation.
Conclusions Clarithromycin is useful to suppress allograft remodeling, because it is critically involved in the prevention of car-
diac rejection through the suppression of MMP-9. (J Am Coll Cardiol 2008;51:1977–85) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.050m
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Mcute cardiac rejection is still a major complication of heart
ransplantation. Inflammatory factors such as cytokines,
hemokines, and adhesion molecules play a critical role in
he development of acute rejection (1–3). The allografts
how diffuse arterial neointimal formation (graft arterial
isease [GAD]), that consists of smooth muscle cells
SMCs), extracellular matrix (ECM), and variously mono-
uclear leukocytes during long-term observation. Although
AD ultimately culminates in vascular stenosis and isch-
mic graft failure, the infallible care and prevention mea-
ures are still unknown.
rom the Departments of *Cardiovascular Medicine and †Thoracic Surgery, Tokyo
edical and Dental University, Tokyo, Japan. This work was supported by grants
rom the Japan Cardiovascular Research Foundation, a Grant-in-aid from the
apanese Ministry of Education, Science and Culture, a Grant-in-aid from the
apanese Ministry of Welfare, and the Organization for Pharmaceutical Safety and
esearch.i
Manuscript received October 17, 2007; revised manuscript received December 13,
007, accepted January 21, 2008.Clarithromycin (CAM) is known as a 14-member ring
acrolide and a potent antibiotic for the treatment of
arious microbial infections. Recently, CAM has been
eported to have multiple biologic effects, such as alteration
f inflammatory factors (4,5). Many inflammatory cells,
uch as lymphocytes (6,7) and monocytes/macrophages
8,9), produce matrix metalloproteinases (MMPs), and
evels have been shown to be upregulated in grafts with
uman and various mammal organ transplantation (10–12).
he MMPs are a large family of proteinases that proteo-
ytically degrade ECM such as collagen and proteoglycan.
he degradation of ECM is an important event in the
rocess of inflammation and tissue remodeling. A member
f MMPs, MMP-9 (gelatinase B) is known to play an
mportant role in tissue remodeling and the migration of
arious cells, such as SMCs (13,14), macrophages, and
ther cells. Smooth muscle cells are shown to express
MP-2 and -9, and excess activation of MMP-2 and -9nduce the destruction of the ECM and can lead to
u
a
f
m
6
m
g
a
a
l
(
p
r
i
t
t
L
U
H
a
s
w
a
a
m
N
a
A
i
g
e
u
F
p
w
T
fi
I
w
w
F
c
f
S
v
s
g
I
g
m
1
v
S
p
C
w
C
f
3
R
r
n
c
m
i
c
a
n
C
t
n
w
(
p
a
d
f
w
f
W
p
i
b
c
R
t
J
1978 Ogawa et al. JACC Vol. 51, No. 20, 2008
CAM Attenuated Acute and Chronic Rejection May 20, 2008:1977–85pathological remodeling and vas-
cular restenosis. However, little is
known about the role of MMP-9
for acute and chronic rejection in
heart transplantation. This study
demonstrated that CAM sup-
pressed acute and chronic rejection
through the inhibition of the
MMP-9 expression from mono-
nuclear cells and SMCs.
Methods
Reagents. The CAM was kindly
provided by Taisho Toyama
Pharmaceutical Corporation,
Ltd (Tokyo, Japan).
Experimental animals and car-
diac transplantation. The male
BALB/c (H-2d) and C57BL/6
(H-2b) mice (4 to 6 weeks, 20 to
25 g) were obtained from Japan
Clea Corporation (Tokyo, Ja-
pan), and this combination was
sed as the major histocompatibility complex (MHC) total
llomismatch group for analysis of acute rejection (8 animals
or graft survival analysis in each group). A combination of
ale C57BL/6 Bm12 (H-2bm12) and C57BL/6 mice (4 to
weeks, 20 to 25 g) was used as the MHC class II
ismatch group for analysis of chronic rejection (n 6 each
roup). Heterotopic cardiac transplantation was performed
s described previously (15). Recipient mice were given oral
dministration CAM (100 mg/kg/day) twice/day. We se-
ected the dose for mice on the basis of previous papers
16,17). Graft survival and function were evaluated by daily
alpation, and cessation of beating was interpreted as
ejection as previously reported (18). The mortality rate
nduced by surgical or technical failure of this murine heart
ransplant procedure is 2% in our laboratory. This inves-
igation conforms with the Guide for the Care and Use of
aboratory Animals in the Tokyo Medical and Dental
niversity.
istopathology. Histopathological analysis was performed
s described previously (19). We obtained 5 transverse
ections/heart for histopathologic examination. The sections
ere stained with hematoxylin and eosin, Elastica van Gieson,
nd Mallory. The area of myocardium and surrounding tissue
ffected by acute rejection and chronic rejection were deter-
ined with a computer-assisted analyzer (Image-Pro Express,
ikon, Tokyo, Japan). The area ratio (affected/entire area as
percentage) was calculated as described previously (15).
ll data were analyzed in a blind fashion by 2 independent
nvestigators and averaged. Samples from 9 animals in each
roup of the total allomismatch combination and 6 animals in
ach group of the MHC class II mismatch combination were
Abbreviations
and Acronyms
CAM  clarithromycin
GAD  graft arterial
disease
DMEM  Dulbecco’s
modified Eagle’s medium
ICAM  intercellular
adhesion molecule
IL  interleukin
MHC  major
histocompatibility complex
MMP  matrix
metalloproteinase
mRNA  messenger
ribonucleic acid
NF-B  nuclear factor-
kappa B
RNA  ribonucleic acid
SMC  smooth muscle cell
TIMP  tissue inhibitor
metalloproteinasesed for histological analysis. iilm in situ zymography. Film in situ zymography was
erformed as described previously (20). Frozen sections
ere cut to a thickness of 7 m (4 samples in each group).
hese sections were mounted on polyethylenetelephthalate
lm coated with gelatin (FIZ-GN) (Wako Pure Chemical
ndustries, Ltd., Osaka, Japan). As a control, these sections
ere mounted on polyethylenetelephthalate film coated
ith gelatin and an MMP inhibitor (FIZ-GI) (Wako).
rozen sections on these films were incubated in a moist
hamber at 37°C for 6 h. After incubation, these films dried
or 30 min and were then stained with Biebrich Scarlet
tain Solution (Wako) for 4 min. Gelatinolytic activity is
isible as a clear area unstained by Biebrich Scarlet; this
olution stains only gelatin on the film, leaving areas with
elatinolytic activity unstained and bright.
mmunohistochemistry. Sections (4 samples in each
roup) were incubated with primary antibodies against
urine intercellular adhesion molecule (ICAM)-1 (YN1/
.7) (provided by Professor Ko Okumura, Juntendo Uni-
ersity), CD4, CD8, CA11b (BD Biosciences Pharmingen,
an Diego, California), nuclear factor-kappa B (NF-B)
65, or MMP-9 (Santa Cruz Biotechnology, Inc., Santa
ruz, California) at 4°C for 12 h. Antibody-HRP conjugate
as detected with Histofine Simplestain Kit (Nichirei
orporation, Tokyo, Japan), used according to the manu-
acturer’s instructions. Enzyme activity was detected with
-Amino-9-ethylcarbazole.
ibonuclease protection assay. Trizol (Invitrogen Corpo-
ation, Carlsbad, California) was used to isolate total ribo-
ucleic acid (RNA) according to the manufacturer’s proto-
ol. The probe was synthesized by the in vitro transcription
ethod with a Multi-Probe Template Set mCK-1 (Pharm-
ngen), T7 polymerase, and [32P] UTP. Messenger ribonu-
leic acid (mRNA) levels were quantified and normalized
gainst levels of glyceraldehyde-3-phosphate dehydroge-
ases (GAPDH) (4 samples in each group).
ell preparations. Primary SMCs were obtained from
he thoracic aortas of Bm12 mice by the explant tech-
ique described previously (19). The SMCs were grown
ith Dulbecco’s modified Eagle’s medium (DMEM)
Sigma Chemical Corporation, St. Louis, Missouri) sup-
lemented 50 g/ml streptomycin, 50 IU/ml penicillin,
nd 10% fetal bovine serum at 37°C and 5% carbon
ioxide. The J774.1A (BALB/cA) cells were obtained
rom Riken Bioresource Center (Tsukuba, Japan) and
ere grown with RPMI1640 (Sigma) supplemented 10%
etal bovine serum.
estern blotting. Western blot analysis was described
reviously (21). The polyvinylidene difluoride membrane
ncubated with primary antibody MMP-9, MMP-2, and
eta-actin (Santa Cruz). And then, the membrane enhanced
hemiluminescence reagent (Pierce Biotechnology Inc.,
ockford, Illinois). Enhanced chemiluminescence was de-
ected with an LAS-1000 (Fujifilm Corporation, Tokyo,
apan). The data were obtained from 3 independent exper-
ments (4 samples in each group).
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May 20, 2008:1977–85 CAM Attenuated Acute and Chronic Rejectioneverse transcriptase-polymerase chain reaction. Serum-
tarved-J774.1A cells were stimulated with interleukin (IL)-
beta recombinant (10 ng/ml) (R&D Systems, Minneapo-
is, Minnesota). Serum-starved SMCs were stimulated with
DGF-BB (5 ng/ml) (Biosource International, Camarillo,
alifornia). Total RNA were collected 16 h after stimula-
ion and isolated according to the manufacture’s protocol by
rizol (Invitrogen). Complementary deoxyribonucleic acid
as prepared with the reverse transcriptase-polymerase
hain reaction (RT-PCR) kit. The PCR was performed
ith PCR-kit in the presence of oligo-primers for MMP-9,
MP-2, tissue inhibitor metalloproteinase (TIMP)-1, and
APDH. The data were obtained from 3 independent
xperiments (4 samples in each group) (Table 1).
ransmigration assay. The migration assay was performed
s described previously (9,22). Briefly, the assay was
erformed with Transwell chambers (Corning Corpora-
ion, Corning, New York) 24-well tissue culture plates
omposed of 5 m pore polycarbonate filters. The upper
hambers were not coated. The SMCs were seeded at 1 
04 cells/well in 100 l medium. The lower chamber was
lled with 400 l of DMEM medium supplemented with
ng/ml PDGF-BB and 0.5% fetal bovine serum (FBS),
nd then the chambers were incubated at 37°C for 24 h
n 5% carbon dioxide incubator. Cells were counted
nder a microscope, and the cells that migrated to the
ower chamber were examined. The data were obtained
rom 3 independent experiments (4 samples in each
roup).
roliferation assay. The SMCs were seeded on the 96-
ell plates (5  103 cells/well) and then incubated with
MEM supplemented 0.5% FBS and PDGF-BB for 2
ays in incubator. Cell proliferation was then assessed with
he Cell Counting Kit-8 (Dojindo, Kumamoto, Japan)
ccording to the manufacturer’s instructions. Cell prolifer-
tion was expressed as the optical density (15). The data
ere obtained from 3 independent experiments (6 samples
n each group).
tatistical analysis. All data are expressed as mean 
EM. Kaplan-Meier analysis was used to estimate graft
urvival, and the Mann-Whitney U test was used for
urvival differences between the 2 groups. Data were com-
Using RT-PCR Primer Design for Mice
Table 1 Using RT-PCR Primer Design for Mi
Name Sequences
MMP-9 Forward 5=-TGT TCA GCA AGG GGC GTG TC-
Reverse 5=-AAA CAG TCC AAC AAG AAA GG
MMP-2 Forward 5=-GGC CAT GCC ATG GGG CTG GA
Reverse 5=-CCA GTC TGA TTT GAT GCT TC-3
TIMP-1 Forward 5=-CTG GCA TCC TCT TGT TGC TA-3
Reverse 5=-AGG GAT CTC CAG GTG CAC AA-
GAPDH Forward 5=-TGA AGG TCG GTG TGA ACG GA
Reverse 5=-CAT GTA GGC CAT GAG GTC CAC
bp  base pair; GAPDH  glyceraldehyde-3-phosphate dehydrogen
polymerase chain reaction; TIMP  tissue inhibitor metalloproteinaseared, and differences between the 2 groups were analyzedy the Student t test for histopathological analysis and
ibonuclease protection assay. One-way analysis of variance
as used in the SMC proliferation assay and SMC migra-
ion assay. Differences with values of p  0.05 were
onsidered significant.
esults
raft survival prolonged and affected the histopathology
y CAM. In the major mismatch group, nontreated allo-
rafts were acutely rejected (7.3  0.2 days, n  8).
owever, CAM administration significantly prolonged al-
ograft survival (9.7  0.2 days, p  0.05, n  8) in this
odel (Fig. 1). Moderate myocardial cell infiltration was
bserved in nontreated allografts on day 7 (35.7  1.9%,
 9), whereas CAM treatment markedly attenuated myo-
ardial cell infiltration (19.7  3.0%, p  0.05, n  9) (Figs.
A and 2B). Although significant fibrosis was observed in the
ontreated allografts (39.6  1.4%, n  9), CAM treatment
ttenuated fibrosis area (23.4 3.4%, p 0.05, n 9) (Figs.
A and 2B).
In the class II mismatch group, all cardiac allografts kept
eating during the observation period and graft function was
Figure 1 Survival of Cardiac Allografts
Representative data of graft survival in the full allomismatch combination. Mice
treated with clarithromycin (CAM) (open circles) showed prolonged cardiac allo-
graft survival in comparison with the nontreated mice (open squares). Non-
treated allografts were acutely rejected (7.1  0.2 days, n  8). However,
CAM administration statistically prolonged allograft survival (9.7  0.2 days,
n  8). *p  0.05 versus nontreated group.
Molecular Weight GenBank
461 bp NM_013599
762 bp NM_008610
585 bp NM_011593
C-3=
=
983 bp NM_001001303
MP  matrix metalloproteinase; RT-PCR  reverse transcriptase-ce
3=
-3=
-3=
=
=
3=
T TTG G
CAC-3
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CAM Attenuated Acute and Chronic Rejection May 20, 2008:1977–85Figure 2 Pathological Findings
Representative light micrographs of allografts from the nontreated group and the clarithromycin (CAM)-treated group. (A) Representative pathological findings with hematoxylin
and eosin (HE) (a, b, e, and f) and Mallory (c, d, g, and h) stain in full allomismatch allografts. Although myocardial cell infiltration and fibrosis were observed in nontreatment
(a, c, e, and g) on day 7, the CAM treatment (b, d, f, and h) markedly attenuated them. Scale bars  2 mm (a to d) and 50 m (e to h). (B) Representative pathological find-
ings with HE (a and b), Mallory (c and d), and Elastica van Gieson (EvG) (e and f) stain in class II mismatch allografts. Although myocardial cell infiltration, fibrosis, and graft
arterial disease (GAD) were observed in the nontreated allografts (a, c, and e) on day 60, CAM treatment (b, d, and f) markedly attenuated them. Scale bars  2 mm (a to d)
and 25 m (e and f). (C) Quantitative data of cell infiltration (a) and fibrosis (b) in the full allomismatch combination. Quantitative data of cell infiltration (d), fibrosis (e) area,
and percentage of neointimal thickening (c) in the class II mismatch combination. *p  0.05 versus nontreated group.
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May 20, 2008:1977–85 CAM Attenuated Acute and Chronic Rejectionot different between the groups. Pathologically, severe myo-
ardial cell infiltration (33.3 1.6%, n 6) and fibrosis (41.8
0.9%, n  6) were observed in the nontreated group,
hereas CAM treatment significantly suppressed infiltration
15.9  4.1%, n  6, p  0.05 vs. nontreated group) and
brosis (20.0  5.5%, n  6, p  0.05 vs. nontreated group)
Figs. 2C and 2D). The heavy neointimal thickening was
bserved in the coronary arteries of untreated allografts in this
ombination. However, intimal thickening was attenuated in
he CAM-treated group (Fig. 2C [c]).
nhibition of inflammatory factors. Immunohistochemi-
ally, enhancement of CD4, CD8, CD11b, NF-B p65,
nd ICAM-1 expression was observed in the nontreated
llografts of total allomismatch combination. However,
AM treatment markedly attenuated expression of these
actors (Fig. 3).
Ribonuclease protection assay was used to examine ex-
ression of cytokine mRNA from full allomismatch cardiac
rafts on day 7. The mRNA levels of interferon-gamma,
L-6, IL-10, and IL-15 were significantly suppressed in the
AM-treated group compared with those of the nontreated
roup (Figs. 4A and 4B) (n  4 each).
n vivo MMP inhibition. The MMP activity was mark-
dly enhanced in the infiltrated area in the nontreated full
llomismatch group; however, CAM-treated grafts atten-
ated the MMP activity (Fig. 5A). The MMP inhibitor
) films show the non– gelatinase-specific activity.
Immunohistochemically, although the nontreated group
nhanced the MMP-9 expression in the infiltrating cells,
AM suppressed the expression in total allomismatch
ombination (Fig. 5B).
n vitro MMP inhibition. Serum-starved-J774.1A cells
ere stimulated with 10 g/ml IL-1beta recombinant,
nd after 24 h of stimulation the protein was collected.
lthough the control group (supplied IL-1beta and
imethyl sulfoxide as a vehicle) markedly enhanced the
xpression of MMP-9 compared with the native group
nonstimulated), CAM-treated cells significantly sup-
ressed the expression of protein levels. The MMP-2
evels were comparable between the control group and the
AM-treated group (Fig. 6A [a]). The CAM-treated
roup altered the expression of MMP-9 mRNA but not
MP-2 and TIMP-1 mRNA (Fig. 6A [b]).
Also, SMCs showed that MMP-9 mRNA level was
arkedly enhanced in the nontreated cells, whereas CAM
reatment suppressed the expression of MMP-9 mRNA
Fig. 6B). However, CAM treatment did not alter the
RNA levels of MMP-2 and TIMP-1 compared with the
ontrol group.
igration and proliferation of SMCs. In proliferation
ssay of SMCs, PDGF-BB–stimulated SMCs were signif-
cantly proliferated, whereas the CAM treatment (2.0 and
0 mol/l) attenuated the cell proliferation (p  0.05 vs.
ontrol group) (Fig. 7A). The migration assay also showed
hat enhanced migration into the lower wells was observed
n the control group, whereas the CAM-treated group tnhibited the migration (p  0.05 vs. control group) (Figs.
B and 7C).
iscussion
larithromycin is not only a potent antibiotic for the
reatment of various microbial infections but also has
ultiple biologic effects. Although the 16-member ring
acrolide do not have multiple effects, it is believed that the
ultiple effects by a macrolide might be characteristic of
4-member ring macrolides (9,23). In this report, we have
ewly demonstrated that CAM inhibited expression of
MP-9 and suppressed acute and chronic rejection in murine
Figure 3 Immunohistochemistry
Representative immunohistochemistry of allograft from the nontreated group
and the clarithromycin (CAM)-treated group. The sections were incubated with
CD4 (a and b), CD8 (c and d), CD11b (e and f), intercellular adhesion mole-
cule (ICAM)-1 (g and h), and nuclear factor-B (NF-B) p65 (i and j). Although
CD4 (a), CD8 (c), and CD11b (e) cells were observed in nontreatment on
day 7, CAM treatment markedly attenuated them (b, d, and f). The expression
of ICAM-1 (g) and NF-B p65 (i) were observed in nontreatment myocardial
infiltrating area; however, CAM treatment markedly attenuated them (h and j).
Scale bars  50 m (a to j).ransplantation models.
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CAM Attenuated Acute and Chronic Rejection May 20, 2008:1977–85Firstly, we demonstrated that CAM suppressed the
cute rejection in the MHC total allomismatch combi-
ation group. We showed that CAM treatment sup-
ressed MMP-9 and NF-B activity in this allograft
odel with zymography and immunohistochemistry. The
lymphocytes and macrophages are a major component
f the cellular infiltration in allografts rejection (24,25);
hey contribute to the development of tissue injury in
cute inflammatory reaction (25,26). The MMPs play an
mportant role in cell migration (27) and are involved in
he migratory capabilities of inflammatory cells such as
Figure 4 RPA
(A) Representative gels in ribonuclease protection assay (RPA). Messenger
ribonucleic acid (mRNA) was isolated from cardiac allografts on day 7. (B) The
quantitative results. Increase of interleukin (IL)-10, IL-15, IL-6, and interferon
(INF)-gamma mRNA levels were observed. However, clarithromycin (CAM) treat-
ment markedly attenuated them. *p  0.05 versus nontreated group. GAPDH
 glyceraldehyde-3-phosphate dehydrogenase.-cells (6). The MMP-9 is known to be especiallymportant in inflammation, and the gelatinase have been
hown to play a critical role in the process of the
nfiltration in inflamed tissues (28). We demonstrated
hat CAM attenuated CD4, CD8, and CD11b cell
nfiltration, altered the expression of inflammatory cyto-
ines, and consequently decreased the infiltration and
brosis compared with the control group in cardiac
llografts. It has previously been reported that CAM
nhibits the activation of NF-B and activator protein-1
4,5). The interaction between ICAM-1 and the receptor
ymphocyte function-associated antigen-1 affects both
lloantigen specific and nonspecific phases of graft de-
truction after heart transplantation. The ICAM-1 is
egulated by NF-B, which is a key transcription factor
f inflammation or immunosuppression (29). At this
oint, there has been no report to compare the immuno-
ogical effects in transplantation between CAM and
mmunosuppressive agents directly in vivo. However,
here was a report to clarify the difference between CAM
nd immunosuppressive drugs such as FK506 in vitro
30). The article demonstrated that CAM could modify
Figure 5 MMP Activity
(A) Representative results of gelatinase’s activity. In the matrix metallopro-
teinases (MMPs) inhibitor () group, gelatinase’s activity was generally
observed in the myocardial infiltrating area in full allografts (a). However,
clarithromycin (CAM) treatment markedly attenuated gelatinase’s activity
(b). The MMPs inhibitor () films show the non–gelatinase-specific activity
(c and d). Scale bars  4 mm (a to d). (B) Representative results of
immunohistochemistry. Although expression of MMP-9 was observed in the
infiltrating cells in nontreatment allografts (a), CAM treatment suppressed
the expression (b). Scale bars  50 m (a and b).
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May 20, 2008:1977–85 CAM Attenuated Acute and Chronic Rejection-cell proliferation and IL-2 production. This showed
hat CAM has similar effects on FK506. However, they
lso showed that combined treatment with CAM (1.6 to
0 g/ml) and FK506 (0.0001 to 0.001 g/ml) resulted
n an additional inhibition of T-cell proliferation. These
esults suggest that pharmacokinetics is significantly
ifferent, and there are different immunological receptors
r signal cascades between CAM and FK506. Further
tudies would be needed to compare the immunological
Figure 6 In Vitro MMP-9 Inhibition
(A) Representative Western blot data detecting the expression of matrix metallo-
proteinases (MMP)-9 and -2 proteins in macrophages (a). The control group (Co)
markedly enhanced the expression of MMP-9 compared with native (Na). The 0.2-
and 20-mol/l clarithromycin (CAM) treatment (0.2 CA and 20 CA) altered the
MMP-9 protein levels compared with the control group. However, MMP-2 expres-
sion was not altered by CAM treatment. (b) Representative gels showed the
expression of MMP-9, MMP-2, and tissue inhibitor metalloproteinase (TIMP)-1 mes-
senger ribonucleic acid (mRNA) levels by reverse transcriptase-polymerase chain
reaction (RT-PCR). The CAM treatment altered the expression of MMP-9 but not
MMP-2 and TIMP-1. The treatment of 20 mol/l CAM inhibited expression of
MMP-9 more effectively than that of 0.2 mol/l. (B) Representative RT-PCR data
detecting the expression of MMP-9, MMP-2, and TIMP-1 mRNA in the smooth mus-
cle cells (SMCs). The control group markedly expressed MMP-9, and CAM treat-
ment inhibited the expression of MMP-9 mRNA levels. The CAM treatment did not
alter the MMP-2 and TIMP-1 expression. GAPDH  glyceraldehyde-3-phosphate
dehydrogenase.Figure 7 Proliferation and Migration Assays
(A) Quantitative data of proliferation assay. Markedly increase proliferation of the
smooth muscle cells (SMCs) was observed by stimulation of PDGF-BB (Biosource
International, Camarillo, California) compared with those of the native group. The
0.2-mol/l clarithromycin (CAM) treatment did not significantly inhibit the cell prolif-
eration, whereas 2.0- and 20-mol/l CAM treatment significantly inhibited the pro-
liferation compared with the control group. *p  0.05 versus control group. (B)
Representative light micrographs of migration assay. Although the SMCs markedly
migrated to a lower well by the stimulation of PDGF-BB (b) compared with those in
the native group (a), CAM (20 mol/l) treatment (c) significantly suppressed the
SMC migration. (C) The quantitative data of migration assay. Counts of SMCs in a
lower well significantly decreased in CAM-treatment group compared with the con-
trol group. *p  0.05 versus control group.
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CAM Attenuated Acute and Chronic Rejection May 20, 2008:1977–85ffects between CAM and conservative immunosuppres-
ive agents.
Secondly, we demonstrated that CAM inhibited the
evelopment of graft arterial disease (GAD) formation in
he MHC class II mismatch combination. Although
AD ultimately culminates in vascular stenosis and
schemic graft failure, the infallible care and prevention
easures are still unknown. Therefore, it is noteworthy
hat CAM, which has been broadly used in clinical
ettings, can suppress the development of GAD that
ould not be prevented with conservative therapies.
hronic MHC class II mismatch allo-responses induce
nflammatory and vascular wall cells to secrete growth
actors that promote SMC intimal recruitment, prolifer-
tion, and matrix synthesis (31,32). Whereas pro-
MP-2 is basally produced by unstimulated SMCs in
itro, MMP-9 are produced after cytokine stimulation
33); MMP-9 is known to be required for SMC migra-
ion (34) and contributing to the intimal thickening
yperplasia of vascular lesion (14,35). The TIMP-1 is
nown as a natural inhibitor of MMP-9, and inhibition
f MMP-9 by TIMP-1 is shown to decrease SMC
igration and subsequent neointimal hyperplasia in the
ascular injury model (36). The NF-B was well known
s the regulator of the MMP-9 and -2; however, our data
howed that CAM attenuated the expression of MMP-9
ut not MMP-2 by Western blot and RT-PCR in
acrophages and SMCs. The results might indicate
ndirect inhibition of NF-B activity by CAM treatment.
n addition, our data showed that CAM attenuated the
xpression of MMP-9 without the alternation of TIMP-1;
AM might have an effect that directly inhibits the
xpression of MMP-9 mRNA without TIMP-1 activa-
ion. Previously, other investigators reported that eryth-
omycin, one of the 14-member ring macrolides, sup-
ressed the production of both MMP-9 and -2 in vitro
9,37). Interestingly, we demonstrated that CAM sup-
ressed the production of MMP-9 but not MMP-2 in
his report. Our data indicate that CAM has the potential
o be a selective MMP-9 inhibitor. However, the detailed
echanism between CAM and MMP-9 has not yet been
lucidated. Further investigation is needed. Although
AM inhibited GAD development and myocardial re-
odeling, graft function was not different between the
roups in the MHC class II mismatch combination.
ecause murine graft function was evaluated by palpation
n this study, this method might lack enough sensitivity
o quantitatively evaluate graft function. An echocardio-
ram would be useful to analyze the function when it is
pplicable in future.
The dosage of CAM we used in this study (100 mg/kg/
ay) was approximately 10 times as large as the clinical
osage (10 to 20 mg/kg/day). Pharmacokinetics of CAM
as different between mice and humans, as previously
eported, and the various doses (5 to 600 mg/kg/day) of
AM could be used for murine examinations (16,17). Thus,e selected the dose for mice. However, further studies
ould be needed to determine an optimal dose-effect
elationship.
We demonstrated for the first time that CAM sup-
ressed myocardial inflammation and fibrosis through the
ttenuation of the inflammatory cell migration and myo-
ardial cell infiltration by inhibition of MMP-9 activity,
hich resulted in suppression of acute cardiac rejection.
n chronic rejection, CAM suppressed GAD develop-
ent through the suppression of SMC proliferation and
igration by MMP-9 inhibition. Although we focused
n MMP-9 in this study, our results could not show
irect evidence that CAM inhibition of MMP-9 was the
rimary effect of the drug. Therefore, further investiga-
ion would be needed to determine the importance of
ther factors that are modified by CAM.
In conclusion, CAM plays a significant role in the preven-
ion of acute and chronic rejection through the inhibition of
MP-9 activity. Clarithromycin might be used in the sup-
ression of transplant rejection and cardiovascular and other
nflammatory diseases in clinical settings.
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